ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) – Stock analysts at Zacks Research issued their FY2025 earnings per share estimates for ImmunoGen in a report released on Wednesday, March 15th. Zacks Research analyst S. Ganoria forecasts that the biotechnology company will earn ($0.15) per share for the year. The consensus estimate for ImmunoGen’s current full-year earnings is ($0.82) per share.
ImmunoGen (NASDAQ:IMGN – Get Rating) last posted its earnings results on Wednesday, March 1st. The biotechnology company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.06. The company had revenue of $41.17 million during the quarter, compared to analyst estimates of $17.18 million. ImmunoGen had a negative return on equity of 100.18% and a negative net margin of 204.93%. The business’s revenue was up 47.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) earnings per share.
ImmunoGen Trading Down 2.9 %
NASDAQ:IMGN opened at $3.96 on Friday. The firm has a market capitalization of $895.16 million, a PE ratio of -4.50 and a beta of 0.94. The stock has a 50 day moving average of $4.33 and a 200-day moving average of $4.96. ImmunoGen has a 52 week low of $3.10 and a 52 week high of $6.63.
Institutional Investors Weigh In On ImmunoGen
A number of institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. lifted its position in ImmunoGen by 0.5% in the fourth quarter. RA Capital Management L.P. now owns 21,853,958 shares of the biotechnology company’s stock worth $108,396,000 after purchasing an additional 112,500 shares during the period. State Street Corp lifted its position in ImmunoGen by 32.8% in the second quarter. State Street Corp now owns 18,199,554 shares of the biotechnology company’s stock worth $81,898,000 after purchasing an additional 4,492,165 shares during the period. BlackRock Inc. lifted its position in ImmunoGen by 10.6% in the first quarter. BlackRock Inc. now owns 16,432,933 shares of the biotechnology company’s stock worth $78,225,000 after purchasing an additional 1,569,629 shares during the period. Vanguard Group Inc. lifted its position in ImmunoGen by 2.3% in the first quarter. Vanguard Group Inc. now owns 15,478,516 shares of the biotechnology company’s stock worth $73,678,000 after purchasing an additional 346,764 shares during the period. Finally, Deerfield Management Company L.P. Series C lifted its position in ImmunoGen by 332.8% in the second quarter. Deerfield Management Company L.P. Series C now owns 15,020,490 shares of the biotechnology company’s stock worth $67,592,000 after purchasing an additional 11,549,815 shares during the period. 89.13% of the stock is currently owned by institutional investors and hedge funds.
ImmunoGen Company Profile
ImmunoGen, Inc engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.